Greater glycogen utilization during 1- than 2-adrenergic receptor stimulation in the isolated perfused rat heart

Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1828-35. doi: 10.1152/ajpendo.00288.2007. Epub 2007 Oct 2.

Abstract

Differences in energy metabolism during beta(1)- and beta(2)-adrenergic receptor (AR) stimulation have been shown to translate to differences in the elicited functional responses. It has been suggested that differential access to glycogen during beta(1)- compared with beta(2)-AR stimulation may influence the peak functional response and modulation of the response during sustained adrenergic stimulation. Interleaved (13)C- and (31)P-NMR spectroscopy was used during beta(1)- and beta(2)-AR stimulation at matched peak workload (2.5 times baseline) in the isolated perfused rat heart to monitor glycogen levels, phosphorylation potential, and intracellular pH. Simultaneous measurements of left ventricular (LV) function [LV developed pressure (LVDP)], heart rate (HR), and rate-pressure product (RPP = LVDP x HR) were also performed. The heart was perfused under both substrate-free (SF) conditions and with exogenous glucose (G). The greater glycogenolysis was observed during beta(1)- than beta(2)-AR stimulation with G (54% vs. 38% reduction, P = 0.006) and SF (92% vs. 79% reduction, P = 0.04) perfusions. The greater beta(1)-AR-mediated glycogenolysis was correlated with greater ability to sustain the initial contractile response. However, with SF perfusion, the duration of this ability was limited: excessive early glycogen depletion caused an earlier decline in LVDP and phosphorylation potential during beta(1)- than beta(2)-AR stimulation. Therefore, endogenous glycogen stores are depleted earlier and to a greater extent, despite a slightly weaker overall inotropic response, during beta(1)- than beta(2)-AR stimulation. These findings are consistent with beta(1)-AR-specific PKA-dependent glycogen phosphorylase kinase signaling.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Adrenergic alpha-Agonists / pharmacology
  • Adrenergic alpha-Antagonists / pharmacology
  • Adrenergic beta-1 Receptor Agonists
  • Adrenergic beta-1 Receptor Antagonists
  • Adrenergic beta-2 Receptor Agonists
  • Adrenergic beta-2 Receptor Antagonists
  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Bisoprolol / pharmacology
  • Ethanolamines / pharmacology
  • Glucose / pharmacology
  • Glycogen / metabolism*
  • Glycogenolysis / drug effects
  • Glycogenolysis / physiology
  • Heart / drug effects
  • Heart / physiology
  • Heart Rate / drug effects
  • In Vitro Techniques
  • Magnetic Resonance Spectroscopy
  • Male
  • Models, Biological
  • Myocardium / metabolism*
  • Norepinephrine / pharmacology
  • Perfusion
  • Phosphocreatine / metabolism
  • Prazosin / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Adrenergic, beta-1 / physiology*
  • Receptors, Adrenergic, beta-2 / physiology*
  • Ventricular Function, Left / drug effects

Substances

  • Adrenergic alpha-Agonists
  • Adrenergic alpha-Antagonists
  • Adrenergic beta-1 Receptor Agonists
  • Adrenergic beta-1 Receptor Antagonists
  • Adrenergic beta-2 Receptor Agonists
  • Adrenergic beta-2 Receptor Antagonists
  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Ethanolamines
  • Receptors, Adrenergic, beta-1
  • Receptors, Adrenergic, beta-2
  • Phosphocreatine
  • zinterol
  • Glycogen
  • Glucose
  • Norepinephrine
  • Prazosin
  • Bisoprolol